CAP 1002

Drug Profile

CAP 1002

Alternative Names: Allogeneic adult stem cell therapy for myocardial infarction - Capricor; Allogeneic cardiosphere-derived cells - Capricor; Allogeneic CDCs - Capricor; Allogenic derived cells - Capricor; CAP1002

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Capricor
  • Developer Capricor; Capricor Therapeutics; Medical University of South Carolina
  • Class Anti-inflammatories; Antifibrinolytics; Antifibrotics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Heart failure; Myocardial infarction
  • Phase I/II Cardiomyopathies

Most Recent Events

  • 19 Apr 2018 Pharmacodynamics data from a preclinical study in Duchenne muscular dystrophy released by Capricor Therapeutics
  • 04 Apr 2018 Phase-II clinical trials in Duchenne muscular dystrophy (In adolescents, In adults) in USA (IV) (NCT03406780)
  • 06 Feb 2018 CAP 1002 receives Regenerative Medicine Advanced Therapy designation from the FDA for Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top